Market research
UROV Urovant Sciences Ltd
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 532M
- P/E ratio
- Not available
- Analyst target
- 16.17
- Dividend yield
- 0.0%
- Beta
- 2.34
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- BMG9381B1081
- Market cap
- 532M
- P/E ratio
- Not available
- Analyst target
- 16.17
- Dividend yield
- 0.0%
- Beta
- 2.34
About
About Urovant Sciences Ltd
Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the UROV discussion.
5 years, 4 months ago
Urovant Sciences Ltd is currently in a long term uptrend where the price is trading 24.3% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Urovant Sciences Ltd's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 99.9% to $-47K since the same quarter in the previous year.
Finally, its free cash flow fell by 369.7% to $-111M since the same quarter in the previous year.
Based on the above factors, Urovant Sciences Ltd gets an overall score of 3/5.